The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity

Genes and Development

Volumn 13, Issue 14, 1999, Pages 1822-1833

  Lisztwan, Joanna ^a   Imbert, Georges ^a   Wirbelauer, Christiane ^a   Gstaiger, Matthias ^a   Krek, Wilhelm ^a  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

Author keywords

Cullin; Elongin; SCF E3 ligases; Tumor suppression; Ubiquitination; VHL

Indexed keywords

UBIQUITIN PROTEIN LIGASE;

ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER INHIBITION; CELL DIFFERENTIATION; CELL GROWTH; ENZYME ACTIVITY; GENE INACTIVATION; GROWTH REGULATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; KIDNEY CARCINOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

EID: 0033565672     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.13.14.1822     Document Type: Article

References (46)

1. Aso, T., W.S. Lane, J.W. Conaway, and R.C. Conaway. 1995. Elongin (SIII): A multisubunit regulator of elongation by RNA polymerase II. Science 269: 1439-1443.
2. Aso, T., D. Haque, R.J. Barstead, R.C. Conaway, and J.W. Conaway. 1996. The inducible elongin A elongation activation domain: Structure, function and interaction with the elongin BC complex. EMBO J. 15: 5557-5566.
3. Bai, C., P. Sen, K. Hofmann, L. Ma, M. Goebl, J.W. Harper, and S.J. Elledge. 1996. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 86: 263-274.
4. Banerjee, A., L. Gregori, Y. Xu, and V. Chau. 1993. The bacterially expressed yeast CDC34 gene product can undergo autoubiquitination to form a multiubiquitin chain-linked protein. J. Biol. Chem. 268: 5668-5675.
5. Brodsky, J.L. and A.A. McCracken. 1997. ER-associated proteasome-mediated protein degradation: How two topologically restricted events come together. Trends Cell Biol. 7: 151-156.
6. Duan, D.R., J.S. Humphrey, D.Y. Chen, Y. Weng, J. Sukegawa, S. Lee, J.R. Gnarra, W.M. Linehan, and R.D. Klausner. 1995a. Characterization of the VHL tumor suppressor gene product: Localization, complex formation, and the effect of natural inactivating mutations. Proc. Natl. Acad. Sci. 92:6459-6463.
7. Duan, D.R., A. Pause, W.H. Burgess, T. Aso, D.Y. Chen, K.P. Garrett, R.C. Conaway, J.W. Conaway, W.M. Linehan, and R.D. Klausner. 1995b. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269: 1402-1406.
8. Feldman, R.M., C.C. Correll, K.B. Kaplan, and R.J. Deshaies. 1997. A complex of Cdc4p, Skp1p, and Cdc53p/cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p. Cell 91: 221-230.
9. Garrett, K., T. Aso, J. Bradsher, S. Foundling, W. Lane, R. Conaway, and J. Conaway. 1995. Positive regulation of general transcription factor SIII by a tailed ubiquitin homolog. Proc. Natl. Acad. Sci. 92: 7172-7176.
10. Gnarra, J.R., K. Tory, Y. Weng, L. Schmidt, M.H. Wei, H. Li, F. Latif, S. Liu, F. Chen, F.M. Duh et al. 1994. Mutations of the VHL tumor suppressor gene in renal carcinoma. Nat. Genet. 7: 85-90.
11. Gnarra, J.R., S. Zhou, M.J. Merrill, J.R. Wagner, A. Krumm, E. Papavassiliou, E.H. Oldfield, R.D. Klausner, and W.M. Linehan. 1996. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Natl. Acad. Sci. 93: 10589-10594.
12. Gorospe, M., J.M. Egan, B. Zbar, M. Lerman, L. Geil, I. Kuzmin, and N.J. Holbrook. 1999. Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells. Mol. Cell. Biol. 19: 1289-1300.
13. Harlow, E. and D. Lane. 1988. Antibodies: A laboratory manual Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
14. Iliopoulos, O., A. Kibel, S. Gray, and W.G. Kaelin, Jr. 1995. Tumor suppression by the human von Hippel-Lindau gene product. Nat. Med. 1: 822-826.
15. Iliopoulos, O., A.P. Levy, C. Jiang, W.G. Kaelin, Jr., and M.A. Goldberg. 1996. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. 93: 10595-10599.
16. Iliopoulos, O., M. Ohh, and W.G. Kaelin, Jr. 1998. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc. Natl. Acad. Sci. 95: 11661-11666.
17. Kaelin, W.G., Jr. and E.R. Maher. 1998. The VHL tumor-suppressor gene paradigm. Trends Genet. 14: 423-426.
18. Kamura, T., S. Sato, D. Haque, L. Liu, W.G. Kaelin, Jr., R.C. Conaway, and J.W. Conaway. 1998. The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes & Dev. 12: 3872-3881.
19. Kamura, T., D.M. Koepp, M.N. Conrad, D. Skowyra, R.J. Moreland, O. Iliopoulos, W.S. Lane, W.G. Kaelin, Jr., S.J. Elledge, R.C. Conaway, J.W. Harper, and J.W. Conaway. 1999. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 284: 657-661.
20. Kibel, A., O. Iliopoulos, J.A. DeCaprio, and W.G. Kaelin, Jr. 1995. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269: 1444-1446.
21. Kipreos, E.T., L.E. Lander, J.P. Wing, W.W. He, and E.M. Hedgecock. 1996. cul-1 is required for cell cycle exit in C. elegans and identifies a novel gene family. Cell 85: 829-839.
22. Knebelmann, B., S. Ananth, H.T. Cohen, and V.P. Sukhatme. 1998. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Cancer Res. 58: 226-231.
23. Koepp, D.M., J.W. Harper, and S.J. Elledge. 1999. How the cyclin became a cyclin: Regulated proteolysis in the cell cycle. Cell 97: 431-434.
24. Krek, W. 1998. Proteolysis and the G1-S transition: The SCF connection. Curr. Opin. Genet. Dev. 8: 36-42.
25. Krek, W., G. Maridor, and E.A. Nigg. 1992. Casein kinase II is a predominantly nuclear enzyme. J. Cell. Biol. 116: 43-55.
26. Latif, F., K. Tory, J. Gnarra, M. Yao, F.M. Duh, M.L. Orcutt, T. Stackhouse, I. Kuzmin, W. Modi, L. Geil et al. 1993. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317-1320.
27. Lee, S., M. Neumann, R. Stearman, R. Stauber, A. Pause, G.N. Pavlakis, and R.D. Klausner. 1999. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein. Mol. Cell. Biol. 19: 1486-1497.
28. Levy, A.P., N.S. Levy, and M.A. Goldberg. 1996. Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein. J. Biol. Chem. 271: 25492-25497.
29. Levy, N.S., S. Chung, H. Furneaux, and A.P. Levy. 1998. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J. Biol. Chem. 273: 6417-6423.
30. Lisztwan, J., A. Marti, H. Sutterluety, M. Gstaiger, C. Wirbelauer, and W. Krek. 1998. Association of human CUL-1 and ubiquitin-conjugating enzyme CDC34 with the F-box protein p45SKP2: Evidence for evolutionary conservation in the subunit composition of the CDC34-SCF pathway. EMBO J. 17: 368-383.
31. Lonergan, K.M., O. Iliopoulos, M. Ohh, T. Kamura, R.C. Conaway, J.W. Conaway, and W.G. Kaelin, Jr. 1998. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol. Cell. Biol. 18: 732-741.
32. Lyapina, S.A., C.C. Correll, E.T. Kipreos, and R.J. Deshaies. 1998. Human CUL1 forms an evolutionarily conserved ubiquitin ligase complex (SCF) with SKP1 and an F-box protein. Proc. Natl. Acad. Sci. 95: 7451-7456.
33. Maher, E.R. and W.G. Kaelin, Jr. 1997. von Hippel-Lindau disease. Medicine 76: 381-391.
34. Margottin, F., S.P. Bour, H. Durand, L. Selig, S. Benichou, V. Richard, D. Thomas, K. Strebel, and R. Benarous. 1998. A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol. Cell 1: 565-574.
35. SKP2 and E2F-1 underlies the regulation of E2F-1 degradation. Nat. Cell Biol. 1: 14-19.
36. Ohh, M., R.L. Yauch, K.M. Lonergan, J.M. Whaley, A.O. Stemmer-Rachamimov, D.N. Louis, B.J. Gavin, N. Kley, W.G. Kaelin, Jr., and O. Iliopoulos. 1998. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell 1: 959-968.
37. Ohta, T., J.J. Michel, A.J. Schottelius, and Y. Xiong. 1999. ROC1, a homolog of APC11, represents a family of cullin partners with an associated ubiquitin ligase activity. Mol. Cell 3: 535-541.
38. Patton, E.E., A.R. Willems, and M. Tyers. 1998. Combinatorial control in ubiquitin-dependent proteolysis: Don't Skp the F-box hypothesis. Trends Genet. 14: 236-243.
39. Pause, A., Lee, S., R.A. Worrell, D.Y. Chen, W.H. Burgess, W.M. Linehan, and R.D. Klausner. 1997. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl. Acad. Sci. 94: 2156-2161.
40. Schoenfeld, A., E.J. Davidowitz, and R.D. Burk. 1998. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc. Natl. Acad. Sci. 95: 8817-8822.
41. Siemeister, G., K. Weindel, K. Mohrs, B. Barleon, G. Martiny-Baron, and D. Marme. 1996. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res. 56: 2299-2301.
42. Skowyra, D., K.L. Craig, M. Tyers, S.J. Elledge, and J.W. Harper. 1997. F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell 91: 209-219.
43. Skowyra, D., D.M. Koepp, T. Kamura, M.N. Conrad, R.C. Conaway, J.W. Conaway, S.J. Elledge, and J.W. Harper. 1999. Reconstitution of G1 cyclin ubiquitination with complexes containing SCFGrr1 and rbx1. Science 284: 662-665.
44. Stebbins, C.E., W.G. Kaelin, Jr., and N.P. Pavletich. 1999. Structure of the VHL-ElonginC-ElonginB complex: Implications for VHL tumor suppressor function. Science 284: 455-461.
45. Takagi, Y., A. Pause, R.C. Conaway, and J.W. Conaway. 1997. Identification of elongin C sequences required for interaction with the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 272: 27444-27449.
46. Tan, P., S.Y. Fuchs, A. Chen, K. Wu, C. Gomez, Z. Ronai, and Z.Q. Pan. 1999. Recruitment of a ROC1-CUL1 ubiquitin ligase by Skp1 and HOS to catalyze the ubiquitination of I kappa B alpha. Mol. Cell 3: 527-533.